(Q34104605)

31 July 2017

1 reference

title

Lobaplatin: a new antitumour platinum drug (English)

1 reference

31 July 2017

1 reference

McKeage MJ

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

published in

1 reference

31 July 2017

volume

10

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

119-128

1 reference

Differential antitumor activity and toxicity of isomeric 1,2-diaminocyclohexane platinum (II) complexes

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.1.119

Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.1.119

Induction of the c-myc but not the cH-ras promoter by platinum compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.1.119

Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.1.119

Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.1.119

Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.1.119

Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (lobaplatin; D19466) in intravenous solutions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.1.119

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.1.119

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.1.119

A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.1.119

A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.1.119

Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.1.119

10.1517/13543784.10.1.119

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference